Tysabri in the News with 24th Case of PML
Tysabri has been in the news again this week. Last Friday the European Medicines Agency (EMEA) announced that they would review the benefits and risks for Tysabri. The Committee started a review of the benefits and risks of Tysabri, in view of reports of 23 cases of progressive multifocal leukoencephalopathy (PML) worldwide since... Read more









